Benzinga | Mar 12, 2021 12:03PM EST

Brookline Capital Initiates Coverage On NLS Pharmaceutics with Buy Rating, Announces Price Target of $12

Brookline Capital analyst Raja Kumaraguru initiates coverage on NLS Pharmaceutics (NASDAQ:NLSP) with a Buy rating and announces Price Target of $12.